EDITORIAL: Lilly picks wisely at tough juncture: Lechleiter well-groomed for top job
Lilly picks wisely at tough juncture Lechleiter well-groomed for top job Indianapolis’ business and civic leaders are rightfully worried about Eli Lilly and Co. these days. The entire pharmaceutical industry is under extraordinary pressure, in part because the blockbusters that have been its lifeblood aren’t gushing out of development pipelines anymore. Lilly faces the monstrous task of finding successors to its antipsychotic Zyprexa, whose U.S. and European patents expire in 2011-a milestone that’s expected to send the drug’s sales into…